Updated 10:08 GMT, 30 Oct 2026 SPX 7,720.39 -0.30% NDX 29,402.51 -1.38% VIX 18.37 +6.80% GOLD 4,001.90 -0.73% CL 103.96 +1.92% BTC 77,301.26 -0.61%
Titan Protect
Join the Desk
NAS100 29,403 −1.38% S&P 7,720 −0.30% GOLD $4,002 −0.73% BTC $77,301 −0.61% VIX 18.37 +6.80% latest tape · as of 10:08 UTC
The Screen · Consumer Cyclical · Auto Parts

Gentex Corporation

GNTX · Nasdaq · USD · Market cap $4.5B · 6,398 employees

Gentex Corporation designs, develops, manufactures, markets, and supplies digital vision, connected car, dimmable glass, fire protection technologies, audio products, medical devices, and consumer electronics.

Not yet scored
20.66 USD

Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 7 days ago

Screened 2026-10-23 · the tape above runs as of 10:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price20.66 USD at the 23 Oct 2026 close
  • Ethical screenNot yet scored
  • OptionsOpen interest leans to puts (put/call 3.09)
  • Last reviewed23 Oct 2026 (7 days ago)

A summary of the dated readings below, not a live quote and not advice.

PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
30.9631.2541.32

What this means: price 20.66 against the desk's fair-value range, base estimate 31.25, over the last year.

Current read
Distribution ?
Screened · screened 2026-10-23
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 3.09, read 2026-10-29
  • Ethical screen not yet scored
Price20.66 USD
Fair value31.25
Ethical score70.0/100
Our investment reviews on this name
2026-10-30Read Distribution20.66+0.0% to today Markdown gives way to Distribution after a 13% slide in 9 weeks
2026-08-31Read Markdown23.65-12.6% to today ✓Distribution gives way to Markdown with volume flow in agreement
2026-07-31Read Distribution24.35-15.2% to today ✓Markup gives way to Distribution after a 6% slide in 4 weeks
2026-07-02Read Markup25.86-20.1% to today First review on file: Markup

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

Daily reads →Latest news →The method →Compare →
The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Gentex Corporation holds its Distribution at $20.66. Consolidating, no directional conviction, held for 229 days.

As held on the ledger · 2026-10-23
PhaseDistribution · caution
Quantitative stateConsolidating, no directional conviction, held for 229 days
Price at the screen$20.66
Valuation11.25 trailing · 9.73 forward price to earnings
Values screenNot scored · score 70.0
Beta0.85
The Workings

Five Screens, Shown in Full

This security has not been fully scored against the values screen yet.

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 0.13% Below 33% Interest-bearing debt is just 0.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 0.18% Below 33% Cash held in interest-bearing accounts and securities is 0.2% of assets, under the one-third limit. Pass
Receivables 17.56% Below 49% Money owed to the company is 17.6% of assets, under the 49% limit. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

The Read, in Plain English

Gentex clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.

2026-10-25

Gentex clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

2026-09-24 Clears

Gentex clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.

Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.

What the Numbers Say It Is Worth

The Fair Value Range

30.96Conservative31.25Base case41.32Growth case 20.66Price

Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 51.3% margin of safety to the base estimate.

The Street's Range
20.00Street low 25.00Street average 42.00Street high 20.66Price

Third-party analyst targets: 9 covering, consensus Hold. The average target sits +21% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections
$43.7$31.6$19.5TODAY5y agoPROJECTIONStreet high$42.00 +69%Our fair value$31.25 +26%Conservative$30.96 +25%Street avg$25.00 +1%

Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Auto parts maker looks cheap but cycle lurks

Picture a supplier whose dimming mirrors sit in millions of new cars. When dealers stop ordering, the revenue line drops fast and the low multiple suddenly looks less like a bargain and more like a warning. Gentex shows 17 percent revenue growth, 15 percent margins and 16 percent ROE, yet the opportunity rating stays at none because the business sits squarely in a cyclical corner of autos.

The forward multiple of 11 times earnings and the gap to our $35 fair value appear attractive on paper. Nine analysts still lean buy with a $28 median target. Those figures do not change the fact that peak-cycle earnings often produce exactly this kind of low multiple, only for profits to reset lower when volumes turn.

Currency swings, raw-material costs and the next downturn in vehicle production remain the real risks here. The ethical screen clears, yet the numbers alone do not overcome the sector trap. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E9.7xvery cheap relative to earnings
Trailing P/E11.2xreasonably valued
EPS, trailing1.89
EPS, forward2.18
Revenue growth-1.0%revenue is shrinking
Profit margin15.5%healthy profit margins
Return on equity16.4%a solid return on shareholder capital
FCF yield7.88%
Dividend yield186.00%
Debt to equity0.44minimal debt: a conservative balance sheet
Current ratio3.04comfortably covers its short-term bills
Beta0.85steadier than the market
Short interest, float0.09%
52-week range20.48 - 26.99
Market cap$4.5B
Employees6,398

The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

GNTX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-10-30 Distribution · changed $20.66 -2.8% Entry 16

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.8% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29.

2026-10-23 Markdown $21.26 +0.0% Entry 15

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-22 Markdown $21.26 +0.0% Entry 14

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-21 Markdown $21.26 +0.7% Entry 13

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-20 Markdown $21.11 +0.0% Entry 12

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-19 Markdown $21.11 +0.0% Entry 11

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-18 Markdown $21.11 +0.0% Entry 10

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-17 Markdown $21.11 +0.0% Entry 9

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-16 Markdown $21.11 +0.3% Entry 8

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-14 Markdown $21.04 -4.1% Entry 7

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on GNTX

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in GNTX's Space
GTXGarrett Motion Inc. LKQLKQ Corporation DORMDorman Products, Inc. ATMUAtmus Filtration Technologies Inc. LEALear Corporation MBLYMobileye Global Inc.

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $23.20 +7.1% · $1,071 +7.1%
2 months $21.99 +13.0% · $1,130 +13.0%
3 months $21.19 +17.3% $0.12 $1,178 +17.8%
6 months $23.47 +5.9% $0.24 $1,069 +6.9%
1 year $21.81 +13.9% $0.48 $1,161 +16.1%
2 years $32.81 -24.3% $0.96 $786 -21.4%
3 years $26.18 -5.1% $1.44 $1,004 +0.4%
5 years $31.41 -20.9% $2.40 $867 -13.3%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever GNTX does next, these words stay.

Gentex Corporation · GNTX · Distribution · $20.66
Recorded 2026-10-23 · before the outcome · scored mechanically

All of today's entries → See the running score →
Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.